Amylyx Pharmaceuticals (AMLX) Retained Earnings (2021 - 2025)
Historic Retained Earnings for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Q3 2025 value amounting to -$718.4 million.
- Amylyx Pharmaceuticals' Retained Earnings fell 2622.91% to -$718.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$718.4 million, marking a year-over-year decrease of 2622.91%. This contributed to the annual value of -$606.7 million for FY2024, which is 9894.87% down from last year.
- Per Amylyx Pharmaceuticals' latest filing, its Retained Earnings stood at -$718.4 million for Q3 2025, which was down 2622.91% from -$684.0 million recorded in Q2 2025.
- Over the past 5 years, Amylyx Pharmaceuticals' Retained Earnings peaked at -$155.8 million during Q4 2021, and registered a low of -$718.4 million during Q3 2025.
- Over the past 5 years, Amylyx Pharmaceuticals' median Retained Earnings value was -$353.4 million (recorded in 2022), while the average stood at -$420.1 million.
- Per our database at Business Quant, Amylyx Pharmaceuticals' Retained Earnings crashed by 12728.99% in 2022 and then skyrocketed by 1390.97% in 2023.
- Over the past 5 years, Amylyx Pharmaceuticals' Retained Earnings (Quarter) stood at -$155.8 million in 2021, then plummeted by 127.29% to -$354.2 million in 2022, then increased by 13.91% to -$304.9 million in 2023, then plummeted by 98.95% to -$606.7 million in 2024, then decreased by 18.42% to -$718.4 million in 2025.
- Its last three reported values are -$718.4 million in Q3 2025, -$684.0 million for Q2 2025, and -$642.6 million during Q1 2025.